HarmonIQ Biosciences

HarmonIQ Biosciences is pioneering the world’s first wearable continuous hormone monitoring (CHM) device, offering real-time, minimally invasive tracking of hormones — a major advancement over traditional blood tests and lab-based hormone panels set to disrupt the $54 billion dollar markets of IVF/menopause. HarmonIQ's founding team is led by Mario Sierra, a biochemist and clinical research expert with a degree from UT Austin and extensive industry background spanning medical devices, consumer wearables, and software startups. With this expertise, HarmonIQ is set to build a breakthrough hormone monitoring platform that is poised to transform women’s health, men’s health, and endocrinology research. HarmonIQ is actively forging partnerships with leading research institutions and healthcare providers, and seeking early backing from pre-seed stage investors